Ronald Mitsuyasu, MD
Ronald Mitsuyasu, MD (Program Co-Director/Faculty Mentor) is Professor of Medicine, Division of Hematology-Oncology, Founding Director of the UCLA Center for Clinical AIDS Research and Education (CARE Center), and Associate Director of the UCLA AIDS Institute. Dr. Mitsuyasu is a recognized leader in biomedical research on HIV infection in both domestic and international settings. He is the current Group Chairman of the NCI-sponsored AIDS Malignancy Consortium (AMC), and has served as principal investigator of national and international trials of biologic agents such as interleukin-2, vaccines for HIV, gene therapy studies and antiviral and KS chemotherapy trials in the AIDS Clinical Trials Group (ACTG) and the AMC.
AIDS-related malignancies, Immune-based treatments for HIV infection including cytokine therapy and gene therapy, and bone marrow transplant
Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment. Sinha S, Shekhar RC, Singh G, Shah N, Ahmad H, Kumar N, Sharma SK, Samantaray J, Ranjan S, Ekka M, Sreenivas V, Mitsuyasu RT. BMC Infect Dis. 2012 Jul 31;12:168.
Meeting the challenge of hematologic malignancies in sub-Saharan Africa. Gopal S, Wood WA, Lee SJ, Shea TC, Naresh KN, Kazembe PN, Casper C, Hesseling PB, Mitsuyasu RT. Blood. 2012 May 31;119(22):5078-87.
Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Krishnan S, Schouten JT, Jacobson DL, Benson CA, Collier AC, Koletar SL, Santana J, Sattler FR, Mitsuyasu R; ACTG-ALLRT Protocol Team. Oncology. 2011;80(1-2):42-9.